強直性脊椎炎の世界市場レポート 2025年

強直性脊椎炎市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.2％で87億1,000万米ドルに成長します。予測期間の成長は、個別化医療へのアプローチ、新規生物製剤の開発、早期介入とスクリーニング、生活習慣と食事管理、遠隔医療と遠隔モニタリングに起因すると考えられます。予測期間における主な動向には、バイオシミラーの利用可能性、標的疼痛治療、患者報告アウトカム（pros）の重視、地域支援プログラム、再生医療の探求などがあります。

今後数年間は、老年人口の増加が強直性脊椎炎市場の拡大を牽引すると予想されます。老年人口とは、人口の年齢構成の変化により高齢者の割合が増加することを指します。この人口動態の変化により、60歳以上の人の数と割合が増加しています。強直性脊椎炎の治療と疼痛管理は、この疾患に罹患した高齢者の運動能力の向上と疼痛管理に重要な役割を果たします。例えば、2023年1月、米国に本部を置く国連事務局の一部門である国連経済社会局（UN DESA）は、65歳以上の高齢者の世界人口は2倍以上に増加し、2021年の7億6,100万人から2050年には16億人になると予測していると報告しました。その結果、老人人口の増加が強直性脊椎炎市場の成長に拍車をかけています。

自己免疫疾患の有病率の上昇は、強直性脊椎炎市場をさらに押し上げると思われます。自己免疫疾患は、免疫系が誤って健康な細胞、組織、臓器を攻撃し、損傷させる異常な免疫反応によって引き起こされる幅広い疾患を包括しています。強直性脊椎炎の場合、免疫系が誤って身体自身の組織を標的とするため、炎症と損傷を引き起こし、特に脊椎と骨盤に影響を及ぼします。この自己免疫疾患の発症には、遺伝的素因と環境要因が大きく関わっています。例えば、2023年9月、クローン病と潰瘍性大腸炎患者の生活改善に焦点を当てたカナダを拠点とする組織であるIBD臨床研究センターは、「IBDの影響レポート2023」を発表しました。この報告書によると、2023年の有病率は10万人当たり825人で、32万人以上のカナダ人が炎症性腸疾患（IBD）を患っており、この有病率は毎年2.44％ずつ上昇し、2035年には人口の1.1％（47万人のカナダ人）がIBDと共存すると予測されています。その結果、自己免疫疾患の罹患率の上昇が強直性脊椎炎市場の今後の成長を牽引することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界強直性脊椎炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の強直性脊椎炎市場：成長率分析
• 世界の強直性脊椎炎市場の実績：規模と成長, 2019-2024
• 世界の強直性脊椎炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界強直性脊椎炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の強直性脊椎炎市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鎮痛剤および非ステロイド性抗炎症薬（NSAID）
• 疾患修飾性抗リウマチ薬（DMARDS）
• 生物学的療法
• ステロイド
• 理学療法
• 手術
• 世界の強直性脊椎炎市場分子による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• バイオシミラー
• 小分子
• 世界の強直性脊椎炎市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非経口
• オーラル
• その他のルート
• 世界の強直性脊椎炎市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 少年
• 大人
• 世界の強直性脊椎炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 調査室
• その他のエンドユーザー
• 世界の強直性脊椎炎市場、鎮痛剤と非ステロイド性抗炎症薬（NSAID）の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 市販のNSAID
• 処方NSAID
• 世界の強直性脊椎炎市場、疾患修飾性抗リウマチ薬（DMARD）の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のDMARD
• 標的DMARD
• 世界の強直性脊椎炎市場、生物学的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• TNF阻害剤
• IL-17阻害剤
• 世界の強直性脊椎炎市場ステロイドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口ステロイド
• 注射用ステロイド
• 世界の強直性脊椎炎市場、理学療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 理学療法
• エクササイズプログラム
• 世界の強直性脊椎炎市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節置換手術
• 脊椎手術

第7章 地域別・国別分析

• 世界の強直性脊椎炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の強直性脊椎炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 強直性脊椎炎市場：競合情勢
• 強直性脊椎炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Cedars-Sinai
• Viatris Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• UCB Inc.
• Cipla Inc.
• Zydus Lifesciences Limited
• Celltrion Inc.
• Hetero Labs Ltd.
• UCSF Health

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 強直性脊椎炎市場2029：新たな機会を提供する国
• 強直性脊椎炎市場2029：新たな機会を提供するセグメント
• 強直性脊椎炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the spine and sacroiliac joints, causing inflammation in the joints and entheses, leading to pain, stiffness, and progressive loss of spinal mobility.

The main treatment modalities for ankylosing spondylitis include painkillers and non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biological therapies, steroids, physical therapies, and surgery. Painkillers and NSAIDs are medications that inhibit the production of specific chemicals causing pain and swelling, aiming to relieve pain and reduce inflammation in AS treatment. Biologics, biosimilars, and small molecules are administered through various routes, including parenteral and oral, catering to both juvenile and adult populations. These treatments are employed by hospitals, clinics, research laboratories, and other end-users.

The ankylosing spondylitis market research report is one of a series of new reports from The Business Research Company that provides ankylosing spondylitis market statistics, including ankylosing spondylitis industry global market size, regional shares, competitors with an ankylosing spondylitis market share, detailed ankylosing spondylitis market segments, market trends and opportunities, and any further data you may need to thrive in the ankylosing spondylitis industry. This ankylosing spondylitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ankylosing spondylitis market size has grown strongly in recent years. It will grow from $5.9 billion in 2024 to $6.36 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to hla-b27 discovery, biologic treatments development, pain management approaches, patient advocacy and awareness, NSAIDS and disease modifying drugs

The ankylosing spondylitis market size is expected to see strong growth in the next few years. It will grow to $8.71 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to personalized medicine approach, novel biologics development, early intervention and screening, lifestyle and diet management, telemedicine and remote monitoring. Major trends in the forecast period include biosimilar availability, targeted pain therapies, patient-reported outcomes (pros) emphasis, community support programs, regenerative medicine exploration.

The growing geriatric population is expected to drive the expansion of the ankylosing spondylitis market in the coming years. The geriatric population refers to the increasing proportion of elderly individuals resulting from changes in a population's age structure. This demographic shift has led to a rise in the number and proportion of people over the age of 60. Treatment and medication for ankylosing spondylitis play a crucial role in improving mobility and managing pain in elderly individuals affected by this condition. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a US-based division of the UN Secretariat, reported that the global population of individuals aged 65 and older is projected to more than double, rising from 761 million in 2021 to 1.6 billion by 2050. As a result, the growing geriatric population is fueling the growth of the ankylosing spondylitis market.

The rising prevalence of autoimmune diseases is set to further boost the ankylosing spondylitis market. Autoimmune diseases encompass a wide range of disorders caused by abnormal immune responses, where the immune system mistakenly attacks and damages healthy cells, tissues, and organs. In the case of ankylosing spondylitis, the immune system incorrectly targets the body's own tissues, leading to inflammation and damage, particularly affecting the spine and pelvis. Genetic predisposition and environmental factors are key contributors to the development of this autoimmune condition. For instance, in September 2023, the IBD Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn's disease and ulcerative colitis, published the Impact of IBD Report 2023. The report revealed that with a prevalence rate of 825 per 100,000, over 320,000 Canadians had inflammatory bowel disease (IBD) in 2023, and this prevalence is expected to rise by 2.44% annually, with 1.1% of the population (470,000 Canadians) projected to be living with IBD by 2035. Consequently, the rising incidence of autoimmune diseases will drive the future growth of the ankylosing spondylitis market.

Advancements in therapeutic options are a notable trend gaining traction in the ankylosing spondylitis market. Companies in the ankylosing spondylitis space are continuously innovating new therapeutic solutions to maintain their market presence. For instance, in April 2022, AbbVie Inc., a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration's (FDA) approval of RINVOQ for treating adults with active ankylosing spondylitis (AS). This new oral treatment is intended for patients who have not responded to TNF blockers, providing significant improvements in symptoms such as back pain and physical function. Its rapid efficacy and positive safety profile from clinical trials make it a valuable addition to managing this chronic inflammatory condition, thereby expanding therapeutic options for patients.

Leading companies in ankylosing spondylitis are focusing on developing innovative drugs, such as those based on enzymatic and cellular assays, to treat moderately to severely active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Drugs developed using enzymatic and cellular assays are created and validated by testing their effects on specific enzymes or cell systems, allowing for more targeted and precise treatments. For example, in April 2022, AbbVie Inc. secured FDA approval for RINVOQ as a treatment for ankylosing spondylitis (AS). RINVOQ, a selective JAK inhibitor being investigated across multiple immune-mediated inflammatory conditions, demonstrates heightened inhibitory potency for JAK-1 over JAK-2, JAK-3, and TYK-2, based on enzymatic and cellular assay data.

In July 2023, Superior Biologics, Inc., a US-based specialty pharmacy and home infusion therapy service provider, and Coherus BioSciences, Inc. announced a national distribution agreement. This collaboration aims to distribute YUSIMRY, a biosimilar to Humira, across the US, offering patients an affordable and high-quality treatment for autoimmune conditions like ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease. The partnership also helps employers reduce specialty drug costs by over 85%. Coherus BioSciences Inc. is a US-based biopharmaceutical company that provides YUSIMRY (adalimumab-aqvh), a biosimilar product for treating ankylosing spondylitis (AS).

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ankylosing spondylitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ankylosing spondylitis market consists of sales of nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ankylosing Spondylitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ankylosing spondylitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ankylosing spondylitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ankylosing spondylitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Disease-Modifying Anti-Rheumatic Drugs (DMARDS); Biological Therapies; Steroids; Physical Therapies; Surgery
• 2) By Molecule: Biologics; Biosimilar; Small Molecules
• 3) By Route Of Administration: Parenteral; Oral; Other Routes
• 4) By Application: Juveniles; Adults
• 5) By End User: Hospitals; Clinics; Research Laboratories; Other End Users
• Subsegments:
• 1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs; Prescription NSAIDs
• 2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs; Targeted DMARDs
• 3) By Biological Therapies: TNF Inhibitors; IL-17 Inhibitors
• 4) By Steroids: Oral Steroids; Injectable Steroids
• 5) By Physical Therapies: Physiotherapy; Exercise Programs
• 6) By Surgery: Joint Replacement Surgery; Spinal Surgery
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Pvt. Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ankylosing Spondylitis Market Characteristics

3. Ankylosing Spondylitis Market Trends And Strategies

4. Ankylosing Spondylitis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Ankylosing Spondylitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ankylosing Spondylitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ankylosing Spondylitis Market Growth Rate Analysis
• 5.4. Global Ankylosing Spondylitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ankylosing Spondylitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ankylosing Spondylitis Total Addressable Market (TAM)

6. Ankylosing Spondylitis Market Segmentation

• 6.1. Global Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
• Biological Therapies
• Steroids
• Physical Therapies
• Surgery
• 6.2. Global Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Biosimilar
• Small Molecules
• 6.3. Global Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Oral
• Other Routes
• 6.4. Global Ankylosing Spondylitis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Juveniles
• Adults
• 6.5. Global Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Laboratories
• Other End Users
• 6.6. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Over-The-Counter NSAIDs
• Prescription NSAIDs
• 6.7. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Disease-Modifying Anti-Rheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional DMARDs
• Targeted DMARDs
• 6.8. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Biological Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• TNF Inhibitors
• IL-17 Inhibitors
• 6.9. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Steroids
• Injectable Steroids
• 6.10. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Physical Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physiotherapy
• Exercise Programs
• 6.11. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Joint Replacement Surgery
• Spinal Surgery

7. Ankylosing Spondylitis Market Regional And Country Analysis

• 7.1. Global Ankylosing Spondylitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ankylosing Spondylitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ankylosing Spondylitis Market

• 8.1. Asia-Pacific Ankylosing Spondylitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ankylosing Spondylitis Market

• 9.1. China Ankylosing Spondylitis Market Overview
• 9.2. China Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ankylosing Spondylitis Market

• 10.1. India Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ankylosing Spondylitis Market

• 11.1. Japan Ankylosing Spondylitis Market Overview
• 11.2. Japan Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ankylosing Spondylitis Market

• 12.1. Australia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ankylosing Spondylitis Market

• 13.1. Indonesia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ankylosing Spondylitis Market

• 14.1. South Korea Ankylosing Spondylitis Market Overview
• 14.2. South Korea Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ankylosing Spondylitis Market

• 15.1. Western Europe Ankylosing Spondylitis Market Overview
• 15.2. Western Europe Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ankylosing Spondylitis Market

• 16.1. UK Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ankylosing Spondylitis Market

• 17.1. Germany Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ankylosing Spondylitis Market

• 18.1. France Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ankylosing Spondylitis Market

• 19.1. Italy Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ankylosing Spondylitis Market

• 20.1. Spain Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ankylosing Spondylitis Market

• 21.1. Eastern Europe Ankylosing Spondylitis Market Overview
• 21.2. Eastern Europe Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ankylosing Spondylitis Market

• 22.1. Russia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ankylosing Spondylitis Market

• 23.1. North America Ankylosing Spondylitis Market Overview
• 23.2. North America Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ankylosing Spondylitis Market

• 24.1. USA Ankylosing Spondylitis Market Overview
• 24.2. USA Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ankylosing Spondylitis Market

• 25.1. Canada Ankylosing Spondylitis Market Overview
• 25.2. Canada Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ankylosing Spondylitis Market

• 26.1. South America Ankylosing Spondylitis Market Overview
• 26.2. South America Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ankylosing Spondylitis Market

• 27.1. Brazil Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ankylosing Spondylitis Market

• 28.1. Middle East Ankylosing Spondylitis Market Overview
• 28.2. Middle East Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ankylosing Spondylitis Market

• 29.1. Africa Ankylosing Spondylitis Market Overview
• 29.2. Africa Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ankylosing Spondylitis Market Competitive Landscape And Company Profiles

• 30.1. Ankylosing Spondylitis Market Competitive Landscape
• 30.2. Ankylosing Spondylitis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Ankylosing Spondylitis Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb
• 31.2. Eli Lilly and Company
• 31.3. Gilead Sciences Inc.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Amgen Inc.
• 31.6. Cedars-Sinai
• 31.7. Viatris Inc.
• 31.8. Astellas Pharma Inc.
• 31.9. AstraZeneca plc
• 31.10. UCB Inc.
• 31.11. Cipla Inc.
• 31.12. Zydus Lifesciences Limited
• 31.13. Celltrion Inc.
• 31.14. Hetero Labs Ltd.
• 31.15. UCSF Health

32. Global Ankylosing Spondylitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ankylosing Spondylitis Market

34. Recent Developments In The Ankylosing Spondylitis Market

35. Ankylosing Spondylitis Market High Potential Countries, Segments and Strategies

• 35.1 Ankylosing Spondylitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ankylosing Spondylitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ankylosing Spondylitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer